Lupin launches generic Epzicom tablets in the US

29 Mar 2017 Evaluate

Pharma Major Lupin has launched Abacavir and Lamivudine tablets, 600 mg/300 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier.

The company’s Abacavir and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare Company’s Epzicom tablets, 600 mg/300 mg. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Epzicom tablets had US sales of $388.1 million according to IMS MAT December 2016.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin Share Price

1599.65 -9.55 (-0.59%)
18-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1523.80
Dr. Reddys Lab 5959.10
Cipla 1352.95
Zydus Lifesciences 934.50
Lupin 1599.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.